{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:44:19Z","timestamp":1790376259315,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,18]]},"DOI":"10.7759\/cureus.90403","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T16:19:14Z","timestamp":1755533954000},"source":"Crossref","is-referenced-by-count":1,"title":["Relapse of Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria and Ketonuria Associated With Pre-operative Sodium-Glucose Co-transporters 2 (SGLT-2) Inhibitor Use"],"prefix":"10.7759","author":[{"given":"Basel","family":"Alheijani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad T","family":"Alswaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama T","family":"Al Swaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad B","family":"Alheijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock J","year":"2015","unstructured":"Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015, 38:1638-42. 10.2337\/dc15-1380","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S015","article-title":"15. Diabetes care in the hospital: standards of medical care in diabetes-2021","volume":"44","year":"2021","unstructured":"15. Diabetes care in the hospital. standards of medical care in diabetes-2021. Diabetes Care. 2021, 44:S211-20. 10.2337\/dc21-S015","journal-title":"Diabetes Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5057","article-title":"Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy","volume":"9","author":"Bobrowski D","year":"2021","unstructured":"Bobrowski D, Kumar R, Wu PE, Lapointe-Shaw L. Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy. Clin Case Rep. 2021, 9:e05057. 10.1002\/ccr3.5057","journal-title":"Clin Case Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-016-0261-1","article-title":"The effect of dapagliflozin on renal function in patients with type 2 diabetes","volume":"29","author":"Kohan DE","year":"2016","unstructured":"Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol. 2016, 29:391-400. 10.1007\/s40620-016-0261-1","journal-title":"J Nephrol"},{"key":"ref5","unstructured":"Preoperative cessation of SGLT2i. American College of Cardiology. (2022). Accessed. n.d: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2022\/10\/07\/17\/21\/preoperative-cessation-of-sglt2i."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89752-w","article-title":"SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort","volume":"11","author":"Ata F","year":"2021","unstructured":"Ata F, Yousaf Z, Khan AA, et al.. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci Rep. 2021, 11:10293. 10.1038\/s41598-021-89752-w","journal-title":"Sci Rep"},{"key":"ref7","unstructured":"INVOKAMET- canagliflozin and metformin hydrochloride tablet, film coated. INVOKAMET XR- canagliflozin and metformin hydrochloride tablet, film coated, extended release. (2024). Accessed. n.d: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=6868666b-c25e-40d1-9d1f-306bbe9390c1."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2019.01.001","article-title":"Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors","volume":"45","author":"Jeon JY","year":"2019","unstructured":"Jeon JY, Kim SK, Kim KS, et al.. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors. Diabetes Metab. 2019, 45:453-7. 10.1016\/j.diabet.2019.01.001","journal-title":"Diabetes Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/2324709617710040","article-title":"Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin","volume":"5","author":"Pujara S","year":"2017","unstructured":"Pujara S, Ioachimescu A. Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin. J Investig Med High Impact Case Rep. 2017, 5:2324709617710040. 10.1177\/2324709617710040","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12245-020-0261-8","article-title":"Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report","volume":"13","author":"Fukuda M","year":"2020","unstructured":"Fukuda M, Nabeta M, Muta T, Fukami K, Takasu O. Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report. Int J Emerg Med. 2020, 13:2. 10.1186\/s12245-020-0261-8","journal-title":"Int J Emerg Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0087","article-title":"Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis","volume":"2019","author":"Rafey MF","year":"2019","unstructured":"Rafey MF, Butt A, Coffey B, Reddington L, Devitt A, Lappin D, Finucane FM. Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis. Endocrinol Diabetes Metab Case Rep. 2019, 2019:10.1530\/EDM-19-0087","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-17-0177","article-title":"Prolonged diabetic ketoacidosis associated with canagliflozin","volume":"2018","author":"Sloan G","year":"2018","unstructured":"Sloan G, Kakoudaki T, Ranjan N. Prolonged diabetic ketoacidosis associated with canagliflozin. Endocrinol Diabetes Metab Case Rep. 2018, 2018:10.1530\/EDM-17-0177","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/cd19-0035","article-title":"Sodium-glucose cotransporter 2 inhibitor-associated prolonged euglycemic diabetic ketoacidosis in type 2 diabetes: a case report and literature review","volume":"38","author":"Yehya A","year":"2020","unstructured":"Yehya A, Sadhu A. Sodium-glucose cotransporter 2 inhibitor-associated prolonged euglycemic diabetic ketoacidosis in type 2 diabetes: a case report and literature review. Clin Diabetes. 2020, 38:112-6. 10.2337\/cd19-0035","journal-title":"Clin Diabetes"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.12.007","article-title":"The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management","volume":"65","author":"Nyenwe EA","year":"2016","unstructured":"Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management. Metabolism. 2016, 65:507-21. 10.1016\/j.metabol.2015.12.007","journal-title":"Metabolism"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0002772021","article-title":"SGLT2 inhibitors: physiology and pharmacology","volume":"2","author":"Wright EM","year":"2021","unstructured":"Wright EM. SGLT2 inhibitors: physiology and pharmacology. Kidney360. 2021, 2:2027-37. 10.34067\/KID.0002772021","journal-title":"Kidney360"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/391427-relapse-of-euglycemic-diabetic-ketoacidosis-with-prolonged-glucosuria-and-ketonuria-associated-with-pre-operative-sodium-glucose-co-transporters-2-sglt-2-inhibitor-use","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T16:19:15Z","timestamp":1755533955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/391427-relapse-of-euglycemic-diabetic-ketoacidosis-with-prolonged-glucosuria-and-ketonuria-associated-with-pre-operative-sodium-glucose-co-transporters-2-sglt-2-inhibitor-use"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.90403","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}